![Placeholder Image Placeholder Image](https://prod.arctic.novartis.com/sites/novartis_com/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseAveXis Community Statement on the Global Managed Access Program for AVXS-101
-
Media ReleaseAveXis Community Statement on the Coronavirus Disease (COVID-19)
-
Media ReleaseAveXis Community Statement on Global Managed Access Program for AVXS-101
-
Media ReleaseAveXis Statement on Changes to Senior Leadership Team
-
Media ReleaseNovartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum
-
Media ReleaseNovartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
-
Media ReleaseNovartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)
-
Media ReleaseNovartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
-
Media ReleaseNovartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond
-
Media ReleaseNovartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM
-
Media ReleaseNovartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation
-
Media ReleaseNovartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma
Pagination
- ‹ Previous page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- …
- 28
- › Next page